Q-omics provides the consensus-scored AOX2P profile across patient tissues and cancer cell-line models. AOX2P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, AOX2P is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, AOX2P RNA expression shows 8,995 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, LUAD, and THYM as cancer lineages where AOX2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AOX2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AOX2P survival associations across molecular data types. AOX2P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AOX2P RNA expression–survival associations across cancer types. High AOX2P expression shows unfavorable associations in KICH, LGG, DLBC, KIRC and TGCT, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for AOX2P RNA expression.
This table summarizes AOX2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for AOX2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AOX2P shows lower tumor expression in KICH and CHOL and higher tumor expression in LUAD, BRCA, HNSC and KIRC. The LUAD box plot shows higher AOX2P RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p < 0.001).
This table shows molecular features associated with AOX2P in patient tissues and cancer cell lines. In patient samples, AOX2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
